EW Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 14.91%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Boston Scientific Corp.'s return on equity of 12.46%.

Edwards Lifesciences Corp. has a consensus price target of $95.41, signalling upside risk potential of 10.49%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 29.7%. Given that Boston Scientific Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Boston Scientific Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Edwards Lifesciences Corp.'s net income of $292.3M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.69x while Boston Scientific Corp.'s PE ratio is 52.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.61x versus 7.52x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pulse Biosciences, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of -22540.7%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Pulse Biosciences, Inc.'s return on equity of -73.32%.

Edwards Lifesciences Corp. has a consensus price target of $95.41, signalling upside risk potential of 10.49%. On the other hand Pulse Biosciences, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 65.79%. Given that Pulse Biosciences, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Pulse Biosciences, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Pulse Biosciences, Inc. has a beta of 1.806, suggesting its more volatile than the S&P 500 by 80.579%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Pulse Biosciences, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Pulse Biosciences, Inc. quarterly revenues of $86K. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Pulse Biosciences, Inc.'s net income of -$19.4M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.69x while Pulse Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.61x versus 10,177.90x for Pulse Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 14.18%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Stryker Corp.'s return on equity of 14.06%.

Edwards Lifesciences Corp. has a consensus price target of $95.41, signalling upside risk potential of 10.49%. On the other hand Stryker Corp. has an analysts' consensus of $429.31 which suggests that it could grow by 17.94%. Given that Stryker Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Stryker Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.84 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Edwards Lifesciences Corp.'s net income of $292.3M is lower than Stryker Corp.'s net income of $859M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.69x while Stryker Corp.'s PE ratio is 47.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.61x versus 5.77x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 11.55%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Edwards Lifesciences Corp. has a consensus price target of $95.41, signalling upside risk potential of 10.49%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.92 which suggests that it could grow by 9.16%. Given that Edwards Lifesciences Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Edwards Lifesciences Corp. is more attractive than Zimmer Biomet Holdings, Inc..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1.02% to investors and pays a quarterly dividend of $0.24 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.69x while Zimmer Biomet Holdings, Inc.'s PE ratio is 23.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.61x versus 2.34x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.